Combinatorial therapies improve the therapeutic efficacy of nanoliposomal ceramide for pancreatic cancer

Cancer Biology and Therapy

Volumn 12, Issue 7, 2011, Pages 574-585

  Jiang, Yixing ^a,b   DiVittore, Nicole A ^a,b   Kaiser, James M ^a   Shanmugavelandy, Sriram S ^a   Fritz, Jennifer L ^a   Heakal, Yasser ^a   Tagaram, Hephzibah Rani S ^a   Cheng, Hua ^a,b   Cabot, Myles C ^c   Staveley O'Carroll, Kevin F ^a   Tran, Melissa A ^a   Fox, Todd E ^a   Barth, Brian M ^a   Kester, Mark ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b PENN STATE CANCER INSTITUTE   (United States)

^c JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

Apoptosis; Ceramide; Chemoresistance; D threo PDMP; Gemcitabine; Glucosylceramide synthase; Nanoliposome; Pancreatic cancer; Synergy

Indexed keywords

2 DECANOYLAMINO 3 MORPHOLINO 1 PHENYL 1 PROPANOL; CERAMIDE; CERAMIDE GLUCOSYLTRANSFERASE INHIBITOR; GEMCITABINE; LIPOSOME; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS CANCER; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CERAMIDES; DEOXYCYTIDINE; DRUG CARRIERS; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ENZYME INHIBITORS; FEMALE; GLUCOSYLTRANSFERASES; HUMANS; LIPOSOMES; MAP KINASE SIGNALING SYSTEM; MICE; MICE, NUDE; MORPHOLINES; NANOPARTICLES; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80053427086     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.12.7.15971     Document Type: Article

References (50)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics 2007. CA Cancer J Clin 2007; 57:43- 66; PMID:17237035; DOI:10.3322/canjclin.57. 1.43.
2. Stover TC, Sharma A, Robertson GP, Kester M. Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma. Clin Cancer Res 2005; 11:3465-74; PMID:15867249; DOI:10.1158/1078-0432.CCR-04-1770.
3. Jabr-Milane L, van Vlerken L, Devalapally H, Shenoy D, Komareddy S, Bhavsar M, et al. Multi-functional nanocarriers for targeted delivery of drugs and genes. J Control Release 2008; 130:121-8; PMID:18538887; DOI:10.1016/j.jconrel.2008.04.016.
4. Cho K, Wang X, Nie S, Chen ZG, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 2008; 14:1310-6; PMID:18316549; DOI:10.1158/1078-0432.CCR-07-1441.
5. Segui B, Andrieu-Abadie N, Jaffrezou JP, Benoist H, Levade T. Sphingolipids as modulators of cancer cell death: Potential therapeutic targets. Biochim Biophys Acta 2006; 1758:2104-20.
6. Taha TA, Hannun YA, Obeid LM. Sphingosine kinase: Biochemical and cellular regulation and role in disease. J Biochem Mol Biol 2006; 39:113-31; PMID:16584625; DOI:10.5483/BMBRep.2006.39.2.113.
7. Liu YY, Yu JY, Yin D, Patwardhan GA, Gupta V, Hirabayashi Y, et al. A role for ceramide in driving cancer cell resistance to doxorubicin. FASEB J 2008; 22:2541- 51; PMID:18245173; DOI:10.1096/fj.07-092981.
8. Devalapally H, Duan Z, Seiden MV, Amiji MM. Paclitaxel and ceramide co-administration in biodegradable polymeric nanoparticulate delivery system to overcome drug resistance in ovarian cancer. Int J Cancer 2007; 121:1830-8; PMID:17557285; DOI:10.1002/ijc.22886.
9. Alphonse G, Bionda C, Aloy MT, Ardail D, Rousson R, Rodriguez-Lafrasse C. Overcoming resistance to gamma-rays in squamous carcinoma cells by poly-drug elevation of ceramide levels. Oncogene 2004; 23:2703- 15; PMID:15048093; DOI:10.1038/sj.onc.1207357.
10. Tran MA, Smith CD, Kester M, Robertson GP. Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development. Clin Cancer Res 2008; 14:3571-81; PMID:18519791; DOI:10.1158/1078-0432.CCR-07-4881.
11. Stover T, Kester M. Liposomal delivery enhances short-chain ceramide-induced apoptosis of breast cancer cells. J Pharmacol Exp Ther 2003; 307:468-75; PMID:12975495; DOI:10.1124/jpet.103.054056.
12. Regala RP, Thompson EA, Fields AP. Atypical protein kinase C iota expression and aurothiomalate sensitivity in human lung cancer cells. Cancer Res 2008; 68:5888-95; PMID:18632643; DOI:10.1158/0008-5472.CAN-08-0438.
13. El-Rayes BF, Ali S, Philip PA, Sarkar FH. Protein kinase C: A target for therapy in pancreatic cancer. Pancreas 2008; 36:346-52; PMID:18437080; DOI:10.1097/ MPA.0b013e31815ceaf7.
14. Friday BB, Adjei AA. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res 2008; 14:342-6; PMID:18223206; DOI:10.1158/1078-0432.CCR-07- 4790.
15. Fox TE, Houck KL, O'Neill SM, Nagarajan M, Stover TC, Pomianowski PT, et al. Ceramide recruits and activates protein kinase Czeta (PKCzeta) within structured membrane microdomains. J Biol Chem 2007; 282:12450-7; PMID:17308302; DOI:10.1074/jbc. M700082200.
16. Powell DJ, Hajduch E, Kular G, Hundal HS. Ceramide disables 3-phosphoinositide binding to the pleckstrin homology domain of protein kinase B (PKB)/Akt by a PKCzeta-dependent mechanism. Mol Cell Biol 2003; 23:7794-808; PMID:14560023; DOI:10.1128/ MCB.23.21.7794-808.2003.
17. Bourbon NA, Yun J, Berkey D, Wang Y, Kester M. Inhibitory actions of ceramide upon PKC-epsilon/ ERK interactions. Am J Physiol Cell Physiol 2001; 280:1403-11; PMID:11350735.
18. Tagaram HR, Divittore NA, Barth BM, Kaiser JM, Avella D, Kimchi ET, et al. Nanoliposomal ceramide prevents in vivo growth of hepatocellular carcinoma. Gut 2011; 60:695-701; PMID:21193455; DOI:10.1136/gut.2010.216671.
19. Liu X, Ryland L, Yang J, Liao A, Aliaga C, Watts R, et al. Targeting of survivin by nanoliposomal ceramide induces complete remission in a rat model of NK-LGL leukemia. Blood 2010; 116:4192-201; PMID:20671121; DOI:10.1182/blood- 2010-02- 271080.
20. Nussbaumer P, Hornillos V, Ghobrial M, Ullrich T. An efficient, one-pot synthesis of various ceramide- 1-phosphates from sphingosine-1-phosphate. Chem Phys Lipids 2008; 151:125-8; PMID:18039471; DOI:10.1016/j.chemphyslip.2007.10. 005.
21. Pallis M, Russell N. P-glycoprotein plays a drug-effluxindependent role in augmenting cell survival in acute myeloblastic leukemia and is associated with modulation of a sphingomyelin-ceramide apoptotic pathway. Blood 2000; 95:2897-904; PMID:10779437.
22. Raggers RJ, van Helvoort A, Evers R, van Meer G. The human multidrug resistance protein MRP1 translocates sphingolipid analogs across the plasma membrane. J Cell Sci 1999; 112:415-22; PMID:9885294.
23. Chapman JV, Gouaze-Andersson V, Messner MC, Flowers M, Karimi R, Kester M, et al. Metabolism of short-chain ceramide by human cancer cells-implications for therapeutic approaches. Biochem Pharmacol 2010; 80:308-15; PMID:20385104; DOI:10.1016/j. bcp.2010.04.001.
24. Réjiba S, Wack S, Aprahamian M, Hajri A. K-ras oncogene silencing strategy reduces tumor growth and enhances gemcitabine chemotherapy efficacy for pancreatic cancer treatment. Cancer Sci 2007; 98:1128-36; PMID:17489984; DOI:10.1111/j.1349- 7006.2007.00506.x.
25. Christgen M, Schniewind B, Jueschke A, Ungefroren H, Kalthoff H. Gemcitabine-mediated apoptosis is associated with increased CD95 surface expression but is not inhibited by DN-FADD in Colo357 pancreatic cancer cells. Cancer Lett 2005; 227:193-200; PMID:16112422; DOI:10.1016/j.canlet.2005.01.016.
26. Hering J, Garrean S, Dekoj TR, Razzak A, Saied A, Trevino J, et al. Inhibition of proliferation by omega-3 fatty acids in chemoresistant pancreatic cancer cells. Ann Surg Oncol 2007; 14:3620-8; PMID:17896154; DOI:10.1245/s10434-007-9556-8.
27. Jiang PH, Motoo Y, Sawabu N, Minamoto T. Effect of gemcitabine on the expression of apoptosis-related genes in human pancreatic cancer cells. World J Gastroenterol 2006; 12:1597-602; PMID:16570353.
28. Lau JP, Weatherdon KL, Skalski V, Hedley DW. Effects of gemcitabine on APE/ref-1 endonuclease activity in pancreatic cancer cells, and the therapeutic potential of antisense oligonucleotides. Br J Cancer 2004; 91:1166- 73; PMID:15316562.
29. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. siRNA directed against c-src enhances pancreatic adenocarcinoma cell gemcitabine chemosensitivity. J Am Coll Surg 2004; 198:953-9; PMID:15194078; DOI:10.1016/j.jamcollsurg.2004.01. 037.
30. Ishida M, Sunamura M, Furukawa T, Akada M, Fujimura H, Shibuya E, et al. Elucidation of the relationship of BNIP3 expression to gemcitabine chemosensitivity and prognosis. World J Gastroenterol 2007; 13:4593-7; PMID:17729412.
31. Barth BM, Gustafson SJ, Young MM, Fox TE, Shanmugavelandy SS, Kaiser JM, et al. Inhibition of NADPH oxidase by glucosylceramide confers chemoresistance. Cancer Biol Ther 2010; 10:1126-36; PMID:20935456; DOI:10.4161/cbt.10.11.13438.
32. Holland WL, Miller RA, Wang ZV, Sun K, Barth BM, Bui HH, et al. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat Med 2011; 17:55-63; PMID:21186369; DOI:10.1038/nm.2277.
33. Saddoughi SA, Song P, Ogretmen B. Roles of bioactive sphingolipids in cancer biology and therapeutics. Subcell Biochem 2008; 49:413-40; PMID:18751921; DOI:10.1007/978-1-4020-8831-5-16.
34. Dumitru CA, Sandalcioglu IE, Wagner M, Weller M, Gulbins E. Lysosomal ceramide mediates gemcitabineinduced death of glioma cells. J Mol Med 2009; 87:1123-32; PMID:19763526; DOI:10.1007/s00109- 009-0514-8.
35. Dumitru CA, Weller M, Gulbins E. Ceramide metabolism determines glioma cell resistance to chemotherapy. J Cell Physiol 2009; 221:688-95; PMID:19711353; DOI:10.1002/jcp.21907.
36. Modrak DE, Leon E, Goldenberg DM, Gold DV. Ceramide regulates gemcitabine-induced senescence and apoptosis in human pancreatic cancer cell lines. Mol Cancer Res 2009; 7:890-6; PMID:19531570; DOI:10.1158/1541-7786.MCR- 08-0457.
37. Wu BX, Zeidan YH, Hannun YA. Downregulation of neutral ceramidase by gemcitabine: Implications for cell cycle regulation. Biochim Biophys Acta 2009; 1791:730-9; PMID:19345744.
38. Arlt A, Gehrz A, Muerkoster S, Vorndamm J, Kruse ML, Folsch UR, et al. Role of NFkappaB and Akt/ PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 2003; 22:3243-51; PMID:12761494; DOI:10.1038/sj.onc.1206390.
39. Liptay S, Weber CK, Ludwig L, Wagner M, Adler G, Schmid RM. Mitogenic and antiapoptotic role of constitutive NFkappaB/Rel activity in pancreatic cancer. Int J Cancer 2003; 105:735-46; PMID:12767057; DOI:10.1002/ijc.11081.
40. Mortenson MM, Galante JG, Gilad O, Schlieman MG, Virudachalam S, Kung HJ, et al. BCL-2 functions as an activator of the AKT signaling pathway in pancreatic cancer. J Cell Biochem 2007; 102:1171-9; PMID:17960583; DOI:10.1002/jcb.21343.
41. Bondar VM, Sweeney-Gotsch B, Andreeff M, Mills GB, McConkey DJ. Inhibition of the phosphatidylinositol- 3'-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Ther 2002; 1:989-97; PMID:12481421.
42. Ito D, Fujimoto K, Mori T, Kami K, Koizumi M, Toyoda E, et al. In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer. Int J Cancer 2006; 118:2337-43; PMID:16331623; DOI:10.1002/ ijc.21532.
43. Takeda A, Osaki M, Adachi K, Honjo S, Ito H. Role of the phosphatidylinositol-3′-kinase-akt signal pathway in the proliferation of human pancreatic ductal carcinoma cell lines. Pancreas 2004; 28:353- 8; PMID:15084985; DOI:10.1097/00006676- 200404000-00026.
44. Moog R, Burger AM, Brandl M, Schuler J, Schubert R, Unger C, et al. Change in pharmacokinetic and pharmacodynamic behavior of gemcitabine in human tumor xenografts upon entrapment in vesicular phospholipid gels. Cancer Chemother Pharmacol 2002; 49:356-66; PMID:11976829; DOI:10.1007/s00280- 002-0428-4.
45. Verheij M, van Blitterswijk WJ, Bartelink H. Radiationinduced apoptosis - the ceramide-SAPK signaling pathway and clinical aspects. Acta Oncol 1998; 37:575-81; PMID:9860316; DOI:10.1080/028418698430287.
46. Chmura SJ, Mauceri HJ, Advani S, Heimann R, Beckett MA, Nodzenski E, et al. Decreasing the apoptotic threshold of tumor cells through protein kinase C inhibition and sphingomyelinase activation increases tumor killing by ionizing radiation. Cancer Res 1997; 57:4340-7; PMID:9331096.
47. Chmura SJ, Nodzenski E, Beckett MA, Kufe DW, Quintans J, Weichselbaum RR. Loss of ceramide production confers resistance to radiation-induced apoptosis. Cancer Res 1997; 57:1270-5; PMID:9102212.
48. Selzner M, Bielawska A, Morse MA, Rudiger HA, Sindram D, Hannun YA, et al. Induction of apoptotic cell death and prevention of tumor growth by ceramide analogues in metastatic human colon cancer. Cancer Res 2001; 61:1233-40; PMID:11221856.
49. Altinoglu EI, Russin TJ, Kaiser JM, Barth BM, Eklund PC, Kester M, et al. Near-infrared emitting fluorophore- doped calcium phosphate nanoparticles for in vivo imaging of human breast cancer. ACS Nano 2008; 2:2075-84; PMID:19206454; DOI:10.1021/ nn800448r.
50. Barth BM, Sharma R, Altinoglu EI, Morgan TT, Shanmugavelandy SS, Kaiser JM, et al. Bioconjugation of calcium phosphosilicate composite nanoparticles for selective targeting of human breast and pancreatic cancers in vivo. ACS Nano 2010; 4:1279-87; PMID:20180585; DOI:10.1021/nn901297q.